iTeos Therapeutics, Inc. (NASDAQ:ITOS) Expected to Announce Quarterly Sales of $63.30 Million

Brokerages expect iTeos Therapeutics, Inc. (NASDAQ:ITOSGet Rating) to announce sales of $63.30 million for the current quarter, Zacks Investment Research reports. Four analysts have made estimates for iTeos Therapeutics’ earnings, with the lowest sales estimate coming in at $40.00 million and the highest estimate coming in at $78.10 million. The firm is scheduled to announce its next earnings report on Monday, January 1st.

According to Zacks, analysts expect that iTeos Therapeutics will report full year sales of $282.55 million for the current financial year, with estimates ranging from $160.00 million to $400.00 million. For the next fiscal year, analysts anticipate that the business will post sales of $175.00 million, with estimates ranging from $100.00 million to $260.00 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research firms that follow iTeos Therapeutics.

Separately, Zacks Investment Research downgraded shares of iTeos Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, January 26th.

Shares of ITOS stock traded down $1.55 during mid-day trading on Tuesday, reaching $32.66. 330,141 shares of the company’s stock traded hands, compared to its average volume of 496,116. iTeos Therapeutics has a 12 month low of $17.43 and a 12 month high of $52.43. The firm has a 50 day moving average price of $34.63 and a two-hundred day moving average price of $34.89. The firm has a market capitalization of $1.16 billion, a PE ratio of 5.83 and a beta of 1.91.

In other news, Director Aaron I. Davis bought 30,000 shares of the company’s stock in a transaction that occurred on Tuesday, March 22nd. The stock was bought at an average price of $32.28 per share, with a total value of $968,400.00. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Michel Detheux sold 14,500 shares of the company’s stock in a transaction on Tuesday, January 25th. The stock was sold at an average price of $35.68, for a total transaction of $517,360.00. The disclosure for this sale can be found here. Insiders sold a total of 639,638 shares of company stock valued at $22,540,228 in the last ninety days. 3.95% of the stock is currently owned by insiders.

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Geode Capital Management LLC boosted its holdings in shares of iTeos Therapeutics by 22.3% during the 3rd quarter. Geode Capital Management LLC now owns 347,363 shares of the company’s stock valued at $9,378,000 after purchasing an additional 63,385 shares during the last quarter. Candriam Luxembourg S.C.A. boosted its holdings in shares of iTeos Therapeutics by 4.0% during the 3rd quarter. Candriam Luxembourg S.C.A. now owns 525,244 shares of the company’s stock valued at $14,181,000 after purchasing an additional 20,354 shares during the last quarter. EcoR1 Capital LLC boosted its holdings in shares of iTeos Therapeutics by 25.8% during the 3rd quarter. EcoR1 Capital LLC now owns 1,303,157 shares of the company’s stock valued at $35,185,000 after purchasing an additional 267,293 shares during the last quarter. BlackRock Inc. raised its position in shares of iTeos Therapeutics by 2.7% during the 3rd quarter. BlackRock Inc. now owns 1,558,236 shares of the company’s stock valued at $42,072,000 after buying an additional 41,498 shares in the last quarter. Finally, Strs Ohio raised its position in shares of iTeos Therapeutics by 108.3% during the 4th quarter. Strs Ohio now owns 22,700 shares of the company’s stock valued at $1,056,000 after buying an additional 11,800 shares in the last quarter.

iTeos Therapeutics Company Profile (Get Rating)

Iteos Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2 clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.

Recommended Stories

Get a free copy of the Zacks research report on iTeos Therapeutics (ITOS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for iTeos Therapeutics (NASDAQ:ITOS)

Receive News & Ratings for iTeos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iTeos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.